CDEK
← All drugs Report issue

darunavir

Trade name: prezista

Small moleculeapprovedCOVID-19Fast Track FDA

Approved

Jun 23, 2006

Darunavir (trade name Prezista) is an orally active bis-furan-sulfonamide inhibitor of human immunodeficiency virus (HIV-1) protease. Darunavir was developed by Tibotec Pharmaceuticals (now Janssen R&D Ireland). Darunavir is indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. The drug is co-administered with low-dose ritonavir and other anti-HIV agents. It is the only antiretroviral that has been registered at two different doses, 800/100 mg once-daily or 600/100 mg twice-daily, allowing its administration throughout the entire course of HIV disease, from naive subjects without any HIV-1 resistance to heavily treatment-experienced subjects with widespread triple-class family resistance. — NCATS

Clinical trial activity

203 trials · 148 clinical orgs · 14 marketing orgs

Phase 1
55
Phase 2
85
Phase 3
56
Phase 4
56

Earliest trial started Aug 1, 2001 (NCT00964327)

Timeline

2000s

  1. Jan 1, 2001

    Tibotec — Earliest Phase 2 Sponsor(trial)

  2. Dec 19, 2002

    Johnson and Johnson — IND Organization

  3. Dec 19, 2002

    Johnson and Johnson — IND Organization

  4. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  5. Jan 1, 2005

    Tibotec — Earliest Phase 3 Sponsor(trial)

  6. Jun 23, 2006

    Tibotec — Earliest FDA Approval

  7. Jun 23, 2006

    Johnson and Johnson — NDA Secondary Org

  8. Jun 23, 2006

    Tibotec — NDA Organization

2010s

  1. Oct 21, 2013

    Mylan — Marketing Organization

  2. Oct 7, 2014

    Hetero Labs Ltd — Marketing Organization

  3. Dec 15, 2014

    Lupin — Marketing Organization

  4. Mar 16, 2017

    Cipla — Marketing Organization

  5. Nov 15, 2017

    Teva — Marketing Organization

2020s

  1. Aug 28, 2020

    Dr. Reddy's Laboratories — Marketing Organization

  2. Dec 14, 2020

    Micro Labs Ltd India — Marketing Organization

  3. Aug 24, 2022

    MSN Laboratories — Marketing Organization

  4. Nov 28, 2023

    Aurobindo Pharma — Marketing Organization

  5. Dec 8, 2023

    Amneal Pharmaceuticals — Marketing Organization

  6. Dec 13, 2023

    Zydus Discovery DMCC — Marketing Organization

  7. Jan 21, 2025

    Annora Pharma — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedPriority reviewAcceleratedFast trackJun 23, 2006

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1
Mol. weight
547.67 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • {(1s,2r)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3r,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
  • {(1s,2r)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3r,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
  • (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate
  • (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate
  • (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl n-((1s,2r)-1-benzyl-2-hydroxy-3-(n(1)-isobutylsulfanilamido)propyl)carbamate
  • (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl n-((1s,2r)-1-benzyl-2-hydroxy-3-(n(1)-isobutylsulfanilamido)propyl)carbamate
  • (3r,3as,6ar)-tetrahydro-2h-furo[2,3-b]furan-3-yl (2s,3r)-4-(4-amino-n-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
  • (3r,3as,6ar)-tetrahydro-2h-furo[2,3-b]furan-3-yl (2s,3r)-4-(4-amino-n-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
  • (3r,3as,6ar)-tetrahydro-2h-furo[2,3-b]furan-3-yl (2s,3r)-4-(4-amino-n-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
  • (3r,3as,6ar)-tetrahydro-2h-furo[2,3-b]furan-3-yl (2s,3r)-4-(4-amino-n-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir
  • darunavir / cobicistat
  • darunavir / cobicistat / emtricitabine / tenofovir alafenamide
  • darunavir ethanolate
  • darunavir ethanolate
  • darunavir ethanolate
  • darunavir ethanolate
  • darunavir ethnolate
  • darunavir hydrate
  • darunavirum
  • darunavirum
  • mc-114
  • mc-114
  • n-((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1s,2r,5r)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
  • n-((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1s,2r,5r)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
  • prezista
  • prezista
  • prezista
  • prezista
  • prezista
  • [(s)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((r)-phenylmethyl)-propyl]-carbamic acid (3r,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
  • [(s)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((r)-phenylmethyl)-propyl]-carbamic acid (3r,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
  • tmc114
  • tmc114
  • tmc 114
  • tmc-114
  • tmc-114
  • tmc-114
  • tmc41629
  • tmc41629
  • uic-940t
  • uic-940t

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06747507Phase 3Jun 30, 2025Government of Mozambique, Muhimbili University, SolidarMed, University of London, University of Nairobi
NCT06787976Phase 4Apr 19, 2025Instituto Mexicano del Seguro Social
NCT06338826Phase 2Oct 1, 2024Assistance Publique - Hôpitaux de Paris, Government of France
NCT06337032Phase 4Aug 27, 2024Gilead Sciences
NCT06139796Phase 1/Phase 2 (Phase 2)Jun 30, 2024AMS-PHPT Research Collaboration, Baylor University, Institut National de la Santé Et de la Recherche Médicale, France, PENTA Foundation, University of Zimbabwe
NCT05197075Phase 1Aug 3, 2022Johnson and Johnson
NCT05463783Phase 4Jul 31, 2022East Carolina University, Janssen Pharmaceutica NV
NCT05378906Phase 1Jun 7, 2022—
NCT04718805Phase 1Jan 25, 2021Janssen Pharmaceutica NV
NCT04661397Phase 1Dec 21, 2020Janssen Pharmaceutica NV
NCT04630002Phase 1Oct 28, 2020ViiV Healthcare
NCT04518228Phase 4Oct 15, 2020Boston University, Gilead Sciences, Merck, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institutes of Health (NIH), ViiV Healthcare
NCT04653194Phase 3Sep 30, 2020Chelsea and Westminster Hospital NHS Foundation Trust, Gilead Sciences, Imperial College London, University of London
NCT04435587Phase 4Jul 31, 2020Mahidol University
NCT04442737Phase 4Jul 1, 2020Janssen Pharmaceutica NV
NCT04388904Phase 4Jun 7, 2020Janssen Pharmaceutica NV
NCT04240210Phase 4Jan 31, 2020Janssen Pharmaceutica NV, University of California, Riverside
NCT04252274Phase 3Jan 30, 2020Fudan University
NCT04236453Phase 1Jan 22, 2020Janssen Pharmaceutica NV
NCT04183738Phase 4Jan 6, 2020Janssen Pharmaceutica NV, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), UNITAID, University of New South Wales, ViiV Healthcare
Showing 20 of 203 trials
Page 1 / 11

Organizations

Research & Development (148)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TibotecFor profit352752001
Janssen Pharmaceutica NVFor profit32852008
Gilead SciencesFor profit251742008
Johnson and JohnsonFor profit231842007
French National Agency for Research on AIDS and Viral HepatitisGovernment111122007
MerckFor profit11242007
ViiV HealthcareFor profit11732009
National Institute of Allergy and Infectious Diseases (NIAID)Government10442003
PfizerFor profit8152007
National Institutes of Health (NIH)Government7332003
St Stephens Aids TrustAcademic/Hospital7722007
University of BarcelonaAcademic/Hospital6532005
University of LondonAcademic/Hospital6432007
AIDS Clinical Trials GroupAcademic/Hospital5432008
GlaxoSmithKlineFor profit5122009
University of New South WalesAcademic/Hospital5512010
Bristol-Myers SquibbFor profit4222009
Fundacio Lluita Contra la SIDAAcademic/Hospital4222005
Badalona Hospital Germans Trias i PujolAcademic/Hospital3322005
Boehringer IngelheimFor profit3322007
148 organizations
Page 1 / 8

Marketing (24)

OrganizationOrg typeRelationshipDate
Amneal PharmaceuticalsFor profitMKTGDec 8, 2023
Annora PharmaFor profitMKTGJan 21, 2025
Aurobindo PharmaFor profitMKTGNov 28, 2023
CiplaFor profitMKTGMar 16, 2017
CiplaFor profitSYNNov 28, 2023
Dr. Reddy's LaboratoriesFor profitMKTGAug 28, 2020
Dr. Reddy's LaboratoriesFor profitSYNNov 28, 2023
Hetero Labs LtdFor profitMKTGOct 7, 2014
Hetero Labs LtdFor profitSYNSep 14, 2023
Johnson and JohnsonFor profitNDA2Jun 23, 2006
Johnson and JohnsonFor profitINDDec 19, 2002
LupinFor profitMKTGDec 15, 2014
LupinFor profitSYNSep 29, 2022
LupinFor profitSYNSep 29, 2022
MSN LaboratoriesFor profitMKTGAug 24, 2022
MSN LaboratoriesFor profitSYNNov 28, 2023
Micro Labs Ltd IndiaFor profitMKTGDec 14, 2020
MylanFor profitMKTGOct 21, 2013
MylanFor profitSYNJul 22, 2025
TevaFor profitMKTGNov 15, 2017
TevaFor profitSYNNov 21, 2017
TibotecFor profitNDAJun 23, 2006
Zydus Discovery DMCCFor profitMKTGDec 13, 2023
Zydus Discovery DMCCFor profitSYNDec 13, 2023